Simple, it's currently priced at nearly 90x it's revenue. Even...

Simple, it's currently priced at nearly 90x it's revenue.
Even if they triple their growth this FY, it's still way overvalued.

I think it's a great investment, but just not at the current price.
I also work for one of the largest healthcare companies in the world, getting surgeons to adopt your product is no easy feat and takes time and money. I recommend reading the prospectus, they themselves state another 1-2 years before they are ready to start entering US & China. They also highlight the need for additional funding and investment to break into those markets.

So they are currently generating circa ~$1M from current customer base, how are they going to raise more capital? how long do you think the $5M is going to last before the next cap raise? The company only had a mere $400k in cash before the IPO.

Also keep in mind the moat factor -
Osteopore competitors include Anatomics,Medtronic, KLS Martin, Stryker, Zimmer Biometand J&J Synthes.

Those competitors are multi-billion dollar organizations (I work for one of them *yay for me.).
OSX maybe a good acquisition target or perhaps J&J and Zimmer Biomet are already working on their own products that may/could be far superior? Who knows? I for one wouldn't buy something 90x it's revenue without some strong confidence & due dilligence that OSX has got what it takes to compete with the big boys.

Each to their own, I've seen to many small caps get pumped to the moon and come back to earth once reality sets in.